Clinical trials: Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma, open to volunteers
Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
Patients with newly diagnosed MCL were treated with ZR2 regimen for 3 cycles, followed by 3 cycles of immunochemotherapy, and zebrutinib maintenance therapy for 2 years after the end of induction therapy, in order to improve the…
- Trial name
- NCT05992597
- Testing
- ZR2 RDHAP
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhejiang Cancer Hospital